Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

BACHEM: Chief Commercial Officer Torsten Wöhr leaves the company

BACHEM confirms the departure of Chief Commercial Officer Torsten Wöhr. No further details on the timing of his exit or on his successor were given in the announcement. » More on finanzen.net
BACHEM pays CHF 0.90 dividend for 2025

At its general meeting, BACHEM approved a dividend of CHF 0.90 per share for 2025, an increase of 5.88% from the previous year. A total of CHF 30.73 million will be distributed, but the total payout is nevertheless 48.77% below last year’s level. The dividend yield for 2025 is 1.50%; the share price rose 35.15% over one year (total return including dividend: 38.13%). FactSet analysts expect a dividend of CHF 1.01 for 2026 (expected yield 1.48%). » More on finanzen.net
BACHEM: 100‑franc investment five years ago would be 2.92% down today

If 100 CHF had been invested in BACHEM stock five years ago (closing price then 72.00 CHF), investors would now hold 1.389 shares worth 97.08 CHF (closing price 23 Jan 2026: 69.90 CHF). That corresponds to a loss of 2.92%. BACHEM most recently reported a market capitalization of 5.23 billion CHF; stock splits and dividends were not considered in the calculation. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Bachem Holding AG has already paid €0.98 in dividends. The last payout was in May.

Financials

In the last quarter, Bachem Holding AG had revenue of €353.66M and net profit of €54.46M

(EUR)	June 2026	YoY
Revenue	353.66M	-
Gross profit	88.46M	-
Net profit	54.46M	-
EBITDA	89.12M	-

Fundamentals

Metric	Value
Market capitalization	€6.85B
Number of shares	74.94M
52-week high/low	€115.03 - €53.20
Dividend yield	1.10%
Dividends TTM	€0.98
Beta	0.81
P/E ratio	42.06
PEG ratio	3.76
P/B ratio	4.34
P/S ratio	8.85

Company profile

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

Name	Bachem Holding AG
CEO	Anne-Kathrin Stoller
Headquarters	Bubendorf, bl Switzerland
Website	bachem.com
Sector	Health Care
Industry	Health Care Providers & Services
IPO	07/16/2012
Employees	2,511